Human breath contains many volatile metabolites. However, few breath tests are currently used in the clinic to monitor disease due to bottlenecks in biomarker identification. Here we engineered breath biomarkers for respiratory disease by local delivery of protease-sensing nanoparticles to the lungs. The nanosensors shed volatile reporters upon cleavage by neutrophil elastase, an inflammation-associated protease with elevated activity in lung diseases such as bacterial infection and alpha-1 antitrypsin deficiency. After intrapulmonary delivery into mouse models with acute lung inflammation, the volatile reporters are released and expelled in breath at levels detectable by mass spectrometry. These breath signals can identify diseased mice with high sensitivity as early as 10 min after nanosensor administration. Using these nanosensors, we performed serial breath tests to monitor dynamic changes in neutrophil elastase activity during lung infection and to assess the efficacy of a protease inhibitor therapy targeting neutrophil elastase for the treatment of alpha-1 antitrypsin deficiency.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Pereira, J. et al. Breath analysis as a potential and non-invasive frontier in disease diagnosis: an overview. Metabolites 5, 3–55 (2014).
Amann, A. et al. Analysis of exhaled breath for disease detection. Annu. Rev. Anal. Chem. 7, 455–482 (2014).
van Oort, P. M. et al. The potential role of exhaled breath analysis in the diagnostic process of pneumonia—a systematic review. J. Breath Res. 12, 024001 (2018).
Hanna, G. B., Boshier, P. R., Markar, S. R. & Romano, A. Accuracy and methodologic challenges of volatile organic compound-based exhaled breath tests for cancer diagnosis: a systematic review and meta-analysis. JAMA Oncol. 5, e182815 (2019).
Gaude, E. et al. Targeted breath analysis: exogenous volatile organic compounds (EVOC) as metabolic pathway-specific probes. J. Breath Res. 13, 032001 (2019).
Savarino, V., Vigneri, S. & Celle, G. The 13C urea breath test in the diagnosis of Helicobacter pylori infection. Gut 45, 18–23 (1999).
Lock, J. et al. Interpretation of non-invasive breath tests using 13C-labeled substrates—a preliminary report with 13C-methacetin. Eur. J. Med. Res. 14, 547–550 (2009).
Ghoshal, U. C. How to interpret hydrogen breath tests. J. Neurogastroenterol. Motil. 17, 312–317 (2011).
Timmins, G. S. Stable isotope biomarker breath tests for human metabolic and infectious diseases: a review of recent patent literature. Expert. Opin. Ther. Pat. 26, 1393–1398 (2016).
Lange, J. et al. Volatile organic compound based probe for induced volatolomics of cancers. Angew. Chem. Int. Ed. 58, 17563–17566 (2019).
Raissy, H. H. et al. A proof of concept study to detect urease producing bacteria in lungs using aerosolized 13C-urea. Pediatr. Allergy Immunol. Pulmonol. 29, 68–73 (2016).
Bishai, W. R. & Timmins, G. S. Potential for breath test diagnosis of urease positive pathogens in lung infections. J. Breath Res. 13, 032002 (2019).
Aberle, D. R. et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med. 365, 395–409 (2011).
Fuchs, S. I. et al. Lung clearance index for monitoring early lung disease in alpha-1-antitrypsin deficiency. Respir. Med. 116, 93–99 (2016).
Lagier, J. et al. Current and past strategies for bacterial culture in clinical microbiology. Clin. Microbiol. Rev. 28, 208–236 (2015).
Taggart, C. C., Greene, C. M., Carroll, T. P., O’Neill, S. J. & McElvaney, N. G. Elastolytic proteases: inflammation resolution and dysregulation in chronic infective lung disease. Am. J. Respir. Crit. Care Med. 171, 1070–1076 (2005).
Houghton, A. M. et al. Neutrophil elastase–mediated degradation of IRS-1 accelerates lung tumor growth. Nat. Med. 16, 219–223 (2010).
Kwong, G. A. et al. Mass-encoded synthetic biomarkers for multiplexed urinary monitoring of disease. Nat. Biotechnol. 31, 63–70 (2013).
Kwon, E. J. & Dudani, J. S. Ultrasensitive tumour-penetrating nanosensors of protease activity. Nat. Biomed. Eng. 1, 0054 (2017).
Buss, C. G., Dudani, J. S., Akana, R. T. K., Fleming, H. E. & Bhatia, S. N. Protease activity sensors noninvasively classify bacterial infections and antibiotic responses. EBioMedicine 38, 248–256 (2018).
Loynachan, C. N. et al. Renal clearable catalytic gold nanoclusters for in vivo disease monitoring. Nat. Nanotechnol. 14, 883–890 (2019).
Kirkpatrick, J. D. et al. Urinary detection of lung cancer in mice via noninvasive pulmonary protease profiling. Sci. Transl. Med. 12, eaaw0262 (2020).
Pham, C. T. N. Neutrophil serine proteases: specific regulators of inflammation. Nat. Rev. Immunol. 6, 541–550 (2006).
Rubenfeld, G. D. et al. Incidence and outcomes of acute lung injury. N. Engl. J. Med. 353, 1685–1693 (2005).
Laurell, C.-B. & Eriksson, S. The electrophoretic α1-globulin pattern of serum in α1-antitrypsin deficiency. Scandinav. J. Clin. Lab. Invest. 15, 132–140 (1963).
Kasperkiewicz, P., Poreba, M., Snipas, S. J., Parker, H. & Winterbourn, C. C. Design of ultrasensitive probes for human neutrophil elastase through hybrid combinatorial substrate library profiling. Proc. Natl Acad. Sci. USA 111, 2518–2523 (2014).
Anderson, B. M. et al. Application of a chemical probe to detect neutrophil elastase activation during inflammatory bowel disease. Sci. Rep. 9, 13295 (2019).
Patton, J. S. The lungs as a portal of entry for systemic drug delivery. Proc. Am. Thorac. Soc. 1, 338–344 (2004).
Gursahani, H., Riggs-Sauthier, J., Pfeiffer, J. & Lechuga-Ballesteros, D. Absorption of polyethylene glycol (PEG) polymers: the effect of PEG size on permeability. J. Pharm. Sci. 98, 2847–2856 (2009).
Pelfrêne, A., Cave, M. R., Wragg, J. & Douay, F. In vitro investigations of human bioaccessibility from reference materials using simulated lung fluids. Int. J. Environ. Res. Public Health 14, 112 (2017).
Ng, A. W., Bidani, A. & Heming, T. A. Innate host defense of the lung: effects of lung-lining fluid pH. Lung 182, 297–317 (2004).
Teeguarden, J. G., Bogdanffy, M. S., Covington, T. R., Tan, C. & Jarabek, A. M. A PBPK model for evaluating the impact of aldehyde dehydrogenase polymorphisms on comparative rat and human nasal tissue acetaldehyde dosimetry. Inhal. Toxicol. 20, 375–390 (2008).
Chiu, W. A. et al. Physiologically based pharmacokinetic (PBPK) modeling of interstrain variability in trichloroethylene metabolism in the mouse. Environ. Health Perspect. 122, 456–463 (2014).
Nong, A. et al. Physiologically based modeling of the inhalation pharmacokinetics of ethylbenzene in B6C3F1 mice. J. Toxicol. Environ. Heal. Part A 70, 1838–1848 (2007).
Krishnan, K., Gargas, M. L., Fennell, T. R. & Andersen, M. E. A physiologically based description of ethylene oxide dosimetry in the rat. Toxicol. Ind. Health 8, 121–140 (1992).
Reddy, M. B. et al. Inhalation dosimetry modeling with decamethylcyclopentasiloxane in rats and humans. Toxicol. Sci. 105, 275–285 (2018).
Beauchamp, J. Real-time breath gas analysis for pharmacokinetics: monitoring exhaled breath by on-line proton-transfer-reaction mass spectrometry after ingestion of eucalyptol-containing capsules. J. Breath Res. 4, 026006 (2010).
Stein, R. L. & Strimpler, A. M. Catalysis by human leukocyte elastase. Aminolysis of acyl-enzymes by amino acid amides and peptides. Biochemistry 26, 2238–2242 (1987).
Hammond, P. D., Stutzenberger, F. & Butler, R. N. Use of a disposable syringe as a novel economic breath-collection chamber for mice. Contemp. Top. Lab. Anim. Sci. 37, 70–71 (1998).
Santos, A. M. et al. Role of 13C-urea breath test in experimental model of Helicobacter pylori infection in mice. Helicobacter 16, 320–326 (2011).
Polverino, E., Rosales-mayor, E., Dale, G. E. & Dembowsky, K. The role of neutrophil elastase inhibitors in lung diseases. Chest 152, 249–262 (2017).
Dudani, J. S., Warren, A. D. & Bhatia, S. N. Harnessing protease activity to improve cancer care. Annu. Rev. Cancer Biol. 2, 353–376 (2017).
Sandhaus, R. A. et al. Clinical practice guidelines: the diagnosis and management of alpha-1 antitrypsin deficiency in the adult. J. COPD Found. 3, 668–682 (2016).
Campos, M. A. et al. The biological effects of double-dose alpha-1 antitrypsin augmentation therapy: a pilot study. Am. J. Respir. Crit. Care Med. 200, 318–326 (2019).
Jonigk, D. et al. Anti-inflammatory and immunomodulatory properties of α1-antitrypsin without inhibition of elastase. Proc. Natl Acad. Sci. USA 110, 15007–15012 (2013).
Borel, F. et al. Editing out five Serpina1 paralogs to create a mouse model of genetic emphysema. Proc. Natl Acad. Sci. USA 115, 2788–2793 (2018).
Shvartsburg, A. A. et al. Ultrafast differential ion mobility spectrometry at extreme electric fields in multichannel microchips. Anal. Chem. 81, 6489–6495 (2009).
Dudani, J. S., Ibrahim, M., Kirkpatrick, J., Warren, A. D. & Bhatia, S. N. Classification of prostate cancer using a protease activity nanosensor library. Proc. Natl Acad. Sci. USA 115, 8954–8959 (2018).
Ong, T. et al. Use of mass spectrometric vapor analysis to improve canine explosive detection efficiency. Anal. Chem. 89, 6482–6490 (2017).
Gargas, M. L., Burgess, R. J., Voisard, D. E., Cason, G. H. & Andersen, M. E. Partition coefficients of low-molecular-weight volatile chemicals in various liquids and tissues. Toxicol. Appl. Pharmacol. 98, 87–99 (1989).
We thank H. Fleming (MIT) for critical editing of the manuscript; H. Ko (MIT) for assistance with experiments; C. Buss (MIT), M. Zieger (U Mass), D. Kotton (BU) and A. Wilson (BU) for helpful discussion; Q. Smith (MIT) for assistance with confocal imaging; and E. Roche (MIT), J. Dudani and A. Bekdemir (MIT) for feedback on the PBPK model. We thank C. Mueller (U Mass) for providing us with AATD mouse models. We thank the Koch Institute’s Robert A. Swanson (1969) Biotechnology Center for technical support, specifically the Hope Babette Tang (1983) Histology Facility, the Biopolymers & Proteomics Core Facility, and the Microscopy Core Facility. We also thank N. Watson at the Whitehead Institute W.M. Keck Microscopy Facility for her TEM imaging services. This study was supported in part by a Global Health Innovation Partnership (GHIP) grant from the Bill and Melinda Gates Foundation, Massachusetts General Hospital and the Ragon Institute; funding from Janssen Research and Development; and funding from the Kathy and Curt Marble Cancer Research Fund to S.N.B. L.W.C. acknowledges support from the National Institute of Health Pathway to Independence Award (K99 EB28311). M.N.A. thanks the National Science Foundation Graduate Research Fellowship Program for support. S.N.B. is a Howard Hughes Institute Investigator.
S.N.B., L.W.C., M.N.A. and R.R.K. are listed as inventors on patent applications related to the content of this work. S.N.B. holds equity in Glympse Bio and Impilo Therapeutics; is a director at Vertex; consults for Cristal, Maverick and Moderna; and receives sponsored research funding from Johnson and Johnson.
Peer review information Nature Nanotechnology thanks Marcin Drag, Hossam Haick and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Chan, L.W., Anahtar, M.N., Ong, TH. et al. Engineering synthetic breath biomarkers for respiratory disease. Nat. Nanotechnol. 15, 792–800 (2020). https://doi.org/10.1038/s41565-020-0723-4
This article is cited by
Nature Reviews Bioengineering (2023)
Evaluation of IDE-based flexible thin film ZnO sensor for VOC sensing in a custom designed gas chamber at room temperature
Journal of Materials Science: Materials in Electronics (2022)
Nature Reviews Chemistry (2021)
Nature Reviews Cancer (2021)